Covidien Announces Nine-Month Results of DURABILITY Iliac Study, Addition of Iliac Indication for EverFlex™ Stent System at VIVA 2014

LAS VEGAS--()--Covidien plc (NYSE: COV) today announced nine-month results of the DURABILITY Iliac study and addition of the iliac indication for its EverFlex™ stent at the Vascular Interventional Advances (VIVA) 2014 conference. The nine-month results confirm the safety and effectiveness of the EverFlex™ and Protégé™ GPS™ self-expanding stent systems* for the treatment of lesions of the common and external iliac arteries.

"The EverFlex™ and Protégé™ GPS™ self-expanding stent systems demonstrated strong patency rates even in difficult to treat calcified lesions in patients with iliac disease," said Dr. Peter Faries, co-National Principal Investigator, Mount Sinai School of Medicine, New York. "This data, along with the robust EverFlex™ stent data in the superficial femoral artery, speaks to the clinical versatility of the system."

The prospective, multi-center, non-randomized clinical study, which was led by Dr. Faries and Dr. John Rundback, co-National Principal Investigator, Holy Name Medical Center, Teaneck, N.J., enrolled 75 patients at 15 centers in the United States and Europe. Nearly 68 percent of patients included in the trial had moderately to severely calcified lesions. The study demonstrated 100 percent device success, and the primary endpoint was met with no major adverse events (MAE) at 30 days and a MAE rate of 1.3 percent at nine months.

Secondary outcomes were also favorable. The nine month primary patency by Kaplan-Meier analysis (the ability for the treated artery to remain open) was 95.8 percent, and freedom from target vessel revascularization (no repeat procedure) was 98.6 percent. Additionally, investigators evaluated patient quality of life using two common screening tools for peripheral vascular disease, an Ankle Brachial Index (ABI) and Walking Impairment Questionnaire (WIQ). The data from the trial demonstrated significant improvements in ABI and WIQ scores at both 30 days and nine months when compared to the baseline.

The EverFlex™ and Protégé™ GPS™ self-expanding stent systems are Nitinol stent systems that expand to a predetermined diameter to restore blood flow. The EverFlex™ stent, which received iliac FDA approval in 2014, previously received biliary clearance in 2006, and superficial femoral artery (SFA) and proximal popliteal (PPA) approval in 2012.

"The DURABILITY Iliac study further demonstrates how the EverFlex™ self-expanding peripheral stent system can improve blood flow, which may help patients with iliac stenosis reduce pain, regain mobility and improve healing," said Mark Turco, M.D., chief medical officer, Vascular Therapies, Covidien. "The iliac indication for the EverFlex™ stent will provide physicians and patients with a broader solution for treating peripheral vascular disease."

 

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.